BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 38641183)

  • 1. Lymph node targeting strategy using a hydrogel sustained-release system to load effector memory T cells improves the anti-tumor efficacy of anti-PD-1.
    Cui H; Zhao YY; Han YH; Lan Z; Zou KL; Cheng GW; Chen H; Zhong PL; Chen Y; Ma LM; Chen TK; Yu GT
    Acta Biomater; 2024 May; 180():423-435. PubMed ID: 38641183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functionalized biomimetic nanoparticles combining programmed death-1/programmed death-ligand 1 blockade with photothermal ablation for enhanced colorectal cancer immunotherapy.
    Xiao Y; Zhu T; Zeng Q; Tan Q; Jiang G; Huang X
    Acta Biomater; 2023 Feb; 157():451-466. PubMed ID: 36442821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The PD-1/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph Nodes.
    Dammeijer F; van Gulijk M; Mulder EE; Lukkes M; Klaase L; van den Bosch T; van Nimwegen M; Lau SP; Latupeirissa K; Schetters S; van Kooyk Y; Boon L; Moyaart A; Mueller YM; Katsikis PD; Eggermont AM; Vroman H; Stadhouders R; Hendriks RW; Thüsen JV; Grünhagen DJ; Verhoef C; van Hall T; Aerts JG
    Cancer Cell; 2020 Nov; 38(5):685-700.e8. PubMed ID: 33007259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pivotal roles of tumor-draining lymph nodes in the abscopal effects from combined immunotherapy and radiotherapy.
    Liu Z; Yu Z; Chen D; Verma V; Yuan C; Wang M; Wang F; Fan Q; Wang X; Li Y; Ma Y; Wu M; Yu J
    Cancer Commun (Lond); 2022 Oct; 42(10):971-986. PubMed ID: 35962977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy Goes Local: The Central Role of Lymph Nodes in Driving Tumor Infiltration and Efficacy.
    van Pul KM; Fransen MF; van de Ven R; de Gruijl TD
    Front Immunol; 2021; 12():643291. PubMed ID: 33732264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the tumor-draining lymph node with adjuvanted nanoparticles reshapes the anti-tumor immune response.
    Thomas SN; Vokali E; Lund AW; Hubbell JA; Swartz MA
    Biomaterials; 2014 Jan; 35(2):814-24. PubMed ID: 24144906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microspheres Encapsulating Immunotherapy Agents Target the Tumor-Draining Lymph Node in Pancreatic Ductal Adenocarcinoma.
    Han BJ; Murphy JD; Qin S; Ye J; Uccello TP; Garrett-Larsen J; Belt BA; Prieto PA; Egilmez NK; Lord EM; Linehan DC; Mills BN; Gerber SA
    Immunol Invest; 2020 Oct; 49(7):808-823. PubMed ID: 32498585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Yeast-derived nanoparticles remodel the immunosuppressive microenvironment in tumor and tumor-draining lymph nodes to suppress tumor growth.
    Xu J; Ma Q; Zhang Y; Fei Z; Sun Y; Fan Q; Liu B; Bai J; Yu Y; Chu J; Chen J; Wang C
    Nat Commun; 2022 Jan; 13(1):110. PubMed ID: 35013252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models.
    Oba T; Makino K; Kajihara R; Yokoi T; Araki R; Abe M; Minderman H; Chang AE; Odunsi K; Ito F
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34049930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of PD-1 blockade in cervical cancer is related to a CD8
    Heeren AM; Rotman J; Stam AGM; Pocorni N; Gassama AA; Samuels S; Bleeker MCG; Mom CH; Zijlmans HJMAA; Kenter GG; Jordanova ES; de Gruijl TD
    J Immunother Cancer; 2019 Feb; 7(1):43. PubMed ID: 30755279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor-draining lymph nodes are pivotal in PD-1/PD-L1 checkpoint therapy.
    Fransen MF; Schoonderwoerd M; Knopf P; Camps MG; Hawinkels LJ; Kneilling M; van Hall T; Ossendorp F
    JCI Insight; 2018 Dec; 3(23):. PubMed ID: 30518694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor-draining lymph nodes are survival niches that support T cell priming against lymphatic transported tumor antigen and effects of immune checkpoint blockade in TNBC.
    O'Melia MJ; Manspeaker MP; Thomas SN
    Cancer Immunol Immunother; 2021 Aug; 70(8):2179-2195. PubMed ID: 33459842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Central role of tumor-associated CD8+ T effector/memory cells in restoring systemic antitumor immunity.
    Kilinc MO; Gu T; Harden JL; Virtuoso LP; Egilmez NK
    J Immunol; 2009 Apr; 182(7):4217-25. PubMed ID: 19299720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The primordial differentiation of tumor-specific memory CD8
    Huang Q; Wu X; Wang Z; Chen X; Wang L; Lu Y; Xiong D; Liu Q; Tian Y; Lin H; Guo J; Wen S; Dong W; Yang X; Yuan Y; Yue Z; Lei S; Wu Q; Ran L; Xie L; Wang Y; Gao L; Tian Q; Zhou X; Sun B; Xu L; Tang Z; Ye L
    Cell; 2022 Oct; 185(22):4049-4066.e25. PubMed ID: 36208623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design of PD-1-decorated nanocages targeting tumor-draining lymph node for promoting T cell activation.
    Kim GB; Sung HD; Nam GH; Kim W; Kim S; Kang D; Lee EJ; Kim IS
    J Control Release; 2021 May; 333():328-338. PubMed ID: 33794271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced oral versus flank lymph node T cell response parallels anti-PD1 efficacy in head and neck cancer.
    Kono M; Saito S; Rokugo M; Egloff AM; Uppaluri R
    Oral Oncol; 2024 May; 152():106795. PubMed ID: 38599127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Local and Targeted Delivery of Immune Checkpoint Blockade Therapeutics.
    Han X; Li H; Zhou D; Chen Z; Gu Z
    Acc Chem Res; 2020 Nov; 53(11):2521-2533. PubMed ID: 33073988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prodrug hydrogel with tumor microenvironment and near-infrared light dual-responsive action for synergistic cancer immunotherapy.
    Ding M; Fan Y; Lv Y; Liu J; Yu N; Kong D; Sun H; Li J
    Acta Biomater; 2022 Sep; 149():334-346. PubMed ID: 35779775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CU06-1004-Induced Vascular Normalization Improves Immunotherapy by Modulating Tumor Microenvironment
    Park S; Oh JH; Park DJ; Zhang H; Noh M; Kim Y; Kim YS; Kim H; Kim YM; Ha SJ; Kwon YG
    Front Immunol; 2020; 11():620166. PubMed ID: 33584714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Injectable Micelle-Incorporated Hydrogels for the Localized Chemo-Immunotherapy of Breast Tumors.
    Qin X; He L; Feng C; Fan D; Liang W; Wang Q; Fang J
    ACS Appl Mater Interfaces; 2021 Oct; 13(39):46270-46281. PubMed ID: 34550685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.